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ABSTRACT 
Poly (caprolactone fumarate) (PCLF) copolymer has been synthesized by 
polycondensation of biodegradable, biocompatible and FDA approved poly 
(caprolactone) and fumaryl chloride and has been used for tissue 
engineering. In this study, ligand-less PCLF nanoparticles (NPs) were 
evaluated as a drug delivery system (DDS) with a potential of improved 
lymphoma tissue uptake regarding PCLF hydrophobicity. Doxorubicin HCl 
(Dox) release profiles showed a burst release of 27% during initial 6 hours 
following by a desired controlled release of 85% in 4 days in pH 5.8 (tumor 
pH). Empty PCLF NPs did not cause a considerable cytotoxicity on T47D, HT29 
and 3T3NIH model cell lines, indicating the polymer safety. Cytotoxicities of 
Dox loaded PCLF NPs were almost equal to those of Dox alone revealing the 
NPs ability for tumor treatment. Fluorescent microscopy images proved an 
efficient uptake of PCLF NPs by T47D model cells. In vivo images showed two 
days accumulation of PCLF NPs in liver and spleen and specially in lymph 
node rich regions of mouse body after 24 hours of injection. Such 
characteristics made PCLF NPs DDS a promising candidate for treatment of 
lymphoma or other lymphatic disorders. 
INTRODUCTION: Among different kinds of 
nanoparticles (NPs), polymeric NPs are promising 
vehicles for drug delivery because of their high 
stability, drug loading, controlled release and drug 
protection against environmental effects and also their 
easier manipulation for different purposes 1. To reduce 
anticancer wide side effects, tremendous works have 
been done on specifically delivering anticancers to the 
tumor tissues by active (ligand-mediated) or passive 
(ligand-less) targeting. Since tumor vasculature are 
porous and their drainage is low (Enhanced Permeation 
and Retention, EPR, effect) and since NPs have 
prolonged blood circulation time, NPs with 100-200 
nm size can enter and be entrapped and therefore be 
passive targeted into tumor tissues 2, 3.  
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Nevertheless, despite the wide researches in the 
development of NPs, studies on their potential toxicity, 
needs more attention 4. Similarly, the characteristic 
biokinetic behavior of NPs is an attractive quality for 
promising applications in medicine. Their biological 
activity and biokinetics are dependent on many 
parameters: size, shape, chemistry, charge, surface 
modifications, etc. When NPs be ingested, systemic 
uptake of NPs via lymph can occur and they can 
distribute and be taken up by liver, spleen, bone 
marrow, heart or other organs. Due to the ethical 
concerns and also reliable in vivo experiments, in the 
last few decades new technologies such as whole 
animal in vivo imaging have been developed 5.  
In vivo fluorescence imaging uses a sensitive camera to 
detect fluorescence emission from fluorophores in 
whole-body living small animals. To overcome the 
photon attenuation in living tissue, fluorophores with 
long emission at the near-infrared (NIR) region are 
generally preferred, including widely used small 
indocarbocyanine dyes 6, 7 such as the recently 
developed NIR, lipophilic carbocyanine dye, 1, 1′-
dioctadecyl- 3, 3, 3′, 3′-tetramethylindotricarbocyanine 
iodide (DiR). DiR has been used to safely and directly 
label the membranes of human leukemic cell lines, 
primary murine lymphocytes and erythrocytes 8 as well 
as NPs for detection in live animals 9-11 and is also 
approved for clinical use in hepatic function 
examination and fluorescent angiography 12. 
Poly (caprolactone), (PCL), is a biodegradable, bio-
compatible and FDA approved polymer synthesized 
through ring opening polymerization of caprolactone. 
PCL has been used for bioresorbable sutures, scaffolds 
and micro and nanoparticulate drug delivery systems 
13, 14. Several copolymers (polyesters) have been 
synthesized from PCL and a hydrophilic segment, 
degrading by esteric hydrolysis 15, 16. Such a copolymer 
is Poly (caprolactone)-poly (ethylene glycol) used for 
preparation of nanoparticulate drug delivery systems 
17,18. 
In our previous works 19, 20, synthesis and identification 
of poly(caprolactone fumarate) (PCLF) copolymers 
were performed according to Wang et al., (21-24) by 
polycondensation of fumaryl chloride and PCLdiols 
with nominal Mn of 530, 1250 and 2000 g mol-1, 
resulting in PCLFs named as PCLF530, PCLF1250 and 
PCLF2000 (Mw of 6026, 9287 and 11623 g/mol, 
respectively). Moreover, PCLF NPs with average size of 
225 nm, zeta potential of about -40 mV and 
doxorubicin HCl (Dox) loading of 6.8%, were prepared 
and characterized 19. In addition, in a separate work, 
crosslinking of the NPs via fumarate double bonds 25, 26 
was investigated 20. Also it was found that PCLF was an 
easily tunable copolymer, for example by using 
different Mw of PCLdiol, and therefore, it can be 
designed for preparation of delivery systems with 
different purposes. 
 
FIGURE 1: SCHEME OF PCLF 
Since macrophages in reticuloendothelial system tend 
to phagocyte more hydrophobic molecules, we were 
hoping that the hydrophobicity of PCLF NPs can 
enhance their lymphatic uptake and be useful for 
lymphoma therapy via passive targeting. When 
lymphoma occurs, cells in the lymphatic system divide 
too rapidly. Because there is lymph tissue in many 
parts of the body, the cancer cells may involve the 
liver, spleen, or bone marrow 27.  
In this study, the cytotoxicity effect of the PCLF NPs on 
cancerous and normal cells, the ability of cancerous 
cells to uptake PCLF NPs and in vivo distribution of 
these NPs in live mice were evaluated. Since we have 
proved that NPs of PCLF1250 not only possessed a 
lower size than NPs of PCLF2000, but also could load 
more drug than NPs of PCLF530, cell culture tests were 
more focused on the NPs of PCLF1250. Besides, NPs of 
PCLF2000 were used for in vivo experiments because 
of their higher hydrophobicity than two other kinds of 
NPs.  
MATERIALS AND METHODS:  
Materials: Dox, fluorescein isothiocyanate (FITC) and 
MTT were purchased from sigma-aldrich Company. 
Acetone and other chemicals were purchased from 
Merck, Germany and all were of synthesis grade. RPMI 
1640 medium, FBS and Trypsin-EDTA were purchased 
from Gibco company, and DiR was purchased from 
Bioquest company. 
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Preparation of PCLF NPs: The preparation method of 
PCLF NPs and the method of Dox release test were 
reported previously 19. Briefly, acetone containing PCLF 
(0.6 w/v%) was poured into deionized water containing 
Dox (0.1w/v%), to obtain Dox loaded NPs. In this 
paper, the Dox release profile in phosphate buffered 
saline, PBS, pH 5.8 (indicating tumor pH) was obtained 
to compare to that in PBS pH 7.4.  
In vitro cytotoxicity test: The cytotoxicity of PCLF NPs 
was investigated on model cell lines of T47D (breast 
cancer cells), HT29 (colorectal carcinoma cells) and 
NIH3T3 (normal fibroblast cells) using the 
colourimetric MTT in vitro assay. Complete RPMI 1640 
culture medium (Dulbecco's modified essential 
medium, Gibco co.), supplemented with 5% (v/v) fetal 
bovine serum (Gibco co.), and 1% (v/v) antibiotic (2 
mM L-glutamine, 100 U/mL Penicillin and 0.1 mg/mL 
Streptomycin; Gibco) was used. The cryotube content 
was added to 1 ml of the medium in a sterile 15 ml 
falcon tube to diminish the effect of DMSO following 
centrifugation at 2000 rpm to obtain cell pellet.  
Then, 5 ml of the medium was added and transferred 
to a T25 flask under a sterile condition. Cultured cells 
were kept at 37˚C in a humidified 5% CO2 incubator. 
Once the cells reached confluence, the culture medium 
was removed and the cells were rinsed three times 
with sterile PBS (5ml/25cm) to remove the serum. The 
confluent cell layers were enzymatically removed, 
using 2.5 ml of trypsin/EDTA (Gibco, USA). The mixture 
was centrifuged at 2000 rpm in 25˚C for 5 minutes. 2 
ml of the medium was added to the precipitated cells 
(cell pellet).   
Cell viability was assessed by indirect cell count, MTT 
(3-[4,5-dimethylthiazol-2-yl]-2-5diphenyltetrazolium 
bromide) method: MTT solution in buffer converts to 
the insoluble formazan with a purple color in 
mitochondria of the live cells as the effect of 
dehydrogenase enzymes which are existed in MTT. 
Death cells can not convert the MTT to formazan, 
therefore, the level of produced formazan is related to 
the vital cells. Overall, samples, 25 µl of MTT solution 
(4mg/ml PBS), 104 cell/well and 180 µl medium were 
added to every well of a 96-well plate, following by 
incubation at 37˚C and removing the medium 
containing MTT after 48 hours. Then, 100 µl of DMSO 
was added to every well to dissolve the formazan 
crystals. The ratio of added NP suspension to the 
medium was 0.5ml/1.5ml. A colorimetric assay 
measured the level of the dye and the results, light 
absorbances, were determined with a plate reader in 
540 nm (OD540) (ELISA reader: absorbance of surviving 
cells). Each experiment was repeated on three 
separate occasions. Two internal controls were set up 
for each experiment:  
1. An IC50 consisting consisting the dose killing 
50% of cells, and; 
2. IC100 consisting of medium only.  
Background absorbance due to the non-specific 
reaction between test compounds and the MTT 
reagent was deducted from exposed cell values. 
Viability percentage compared to a control without 
treatment was caculated as:  
Viability (%)= Ni/Nc × 100 
Viability %: The percentage of mean number of vital 
cells, Ni: mean light absorbance of three wells of 
samples, Nc: mean light absorbance of three wells of 
controls. 
Dose response curves of in vitro cytotoxicity data were 
obtained. Dose response curves were plotted for the 
test chemicals after correction by subtracting the 
background absorbance from the controls. The sample 
formulations were as follow:  
Sample 1: Suspensions of PCLF530 NPs in RPMI with 
the NP concentration of 6000, 3000 and 1500 µg/ml, 
Sample 2: Suspensions of PCLF1250 NPs in RPMI with 
the NP concentration of 6000, 3000 and 1500 µg/ml,  
Sample 3: Suspensions of PCLF2000 NPs in RPMI with 
the NP concentration of 6000, 3000 and 1500 µg/ml,  
Sample 4: Suspension of Dox loaded PCLF1250 NPs in 
RPMI with the NP concentration of 6000, 3000 and 
1500 µg/ml and the Dox concentration of 60, 30 and 
15 µg/ml, respectively,  
Sample 5: Solutions of Dox in RPMI (as positive control) 
with concentrations of 100 and 250 nM for T47D cells 
and 300 and 500 nM for HT29 cells. 
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Cellular Uptake Test: First, PCLF NPs physically 
encapsulating FITC, were prepared with average size of 
about 200 nm and negative zeta potential. To observe 
uptake of NPs, 100,000 cells were placed in every well 
of a 24-well multiwell plate and incubated for 48 
hours. Then, the samples were added to every well and 
incubated for 48 hours. After that the cells were 
imaged with confocal microscopy (IX71, Olympus, 
Japan) immediately after replacing the particle 
suspension in the medium with fresh particle-free 
medium, to observe the uptake of PCLF NPs. Samples 
used were as follow: Sample 1: A suspension of 
PCLF1250 NPs in RPMI with the NP concentration of 
6000 µg/ml, Sample 2: A suspension of FITC loaded 
PCLF1250 NPs in RPMI with the NP concentration of 
6000 µg/ml and FITC concentration of 0.25 µg/ml. 
In vivo imaging: First, DiR excitation and emission 
wavenumbers were determined by in vivo imaging 
system (Kodak, USA). Then DiR was loaded into PCLF 
NPs by dissolving it in acetone phase during NP 
preparation process. The NPs were isolated by a paper 
filter (PC type, Whatman, UK) with pore size of 0.1 µm 
and the filtrate UV-VS absorbance was read at 741.5 
nm (Jasco V-530, Jasco co., Japan) for determination of 
the concentration of unloaded DiR. The latter amount 
was subtracted from the initially added DiR to acetone 
before the production of NPs and the result was the 
amount of DiR loaded into the NPs. Ultimately, this 
amount of loaded DiR was used to calculate the drug 
loading (DL) and entrapment efficiency (EE) by the 
following equations: 
DL (%) = Amount of drug in NPs / Amount of drug-loaded 
NPs × 100 
EE (%) = Amount of drug in NPs / Total amount of drug × 
100 
The profiles of DiR release from PCLF NPs were 
obtained in PBS pH 7.4 as described in the paragraph 
of PCLF NPs. A whole animal imaging was performed 
on laboratory BALB/c mice after itracardial injection of 
20 µl DiR loaded PCLF NPs (formulations listed in table 
1, passed through a 0.45 µm sterile filter) or DiR 
solution or saline as controls. Anesthesia was delivered 
before every imaging by subcutaneous injection of 
ketamine hydrochloride at dose of 10 mg/kg and 
xylazine at dose of 1 mg/kg. 
TABLE 1: DiR LOADING INTO PCLF NPs 
F. PCLF Mw (w/v%) DiR (w/v%) NP size (nm) PDI Zeta potential (mV) DL% EE% 
1 530,0.6 0.2 126±20.4 0.1 -21.6±7.5 7.6±4 46±24.2 
2 1250,0.6 0.2 270.6±10.2 0.1 -3.3±2 21.6±7 65±21 
3 2000,0.6 0.2 247±6.2 0.1 -9±2 30.6±0.5 92±1.7 
4 PCL2000,0.6 0.2 302.6±34.2 0.2 0.6±0.4 20.3±18.5 61±25.5 
 
Statistical Analysis: The data were presented as mean 
± SD. One-way analysis of variance (ANOVA) was used 
for comparing the mean differences. SPSS for Windows 
(release 11.5.0) was employed for statistical analysis. 
p-value <0.05 was considered to be significant. In this 
study, all of the experiments were performed in 
triplicate, and the averages were considered to be the 
response. 
RESULTS AND DISCUSSION:  
Dox Release Profile: The profile of Dox release in PBS 
pH 5.8 indicating the pH of the tumors, was 
characterized by an initial burst release of 27% in first 
6 hours following by a sustained release of about 85% 
after 4 days to 90% after 7 days, while previously 
reported profile in pH 7.4 contained a constant 
maximum release of about 80% after 4 days (figure 2). 
 
FIGURE 2: PROFILES OF RELEASE OF TRB AND DOX FROM 
FORMULATIONS 15 AND 21 (TABLE 5), RESPECTIVELY, IN PBS (PH 
7.4) AND AT 37˚C.Data are shown as cumulative percent of 
released drug and as mean ± SD (n=3)  
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In vitro Cytotoxicity: Figures 3, 4 and 5 show the cell 
viability (%) after exposuring them to the different 
PCLF NPs or Dox solutions. Each experimental 
rectangle represents the average of a series of three 
different experiments. Cell viability was about 90% 
after T47D, HT29 and NIH3T3 cells were exposured by 
non-loaded PCLF NPs, indicating the safety of the 
polymer for the cells. There were no significant 
different between cell viability for PCLF530, 1250 and 
2000 NPs in all three cell lines (p>0.05). Obviously, cell 
viability was significantly reduced in a dose-dependent 
manner after exposuring the cells to Dox solutions or 
Dox loaded NPs (p<0.05).  
 
FIGURE 3: CELL VIABILITY OF PCLF NPs AFTER 24 H EXPOSURE TO T47D CELLS 
 
FIGURE 4: CELL VIABILITY OF PCLF NPs AFTER 24 H EXPOSURE TO HT29 CELLS 
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Effect of Nanoparticles on NIH 3T3 cells in Comparison to Doxorubocin
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FIGURE 5: CELL VIABILITY OF PCLF NPs AFTER 24 H EXPOSURE TO NIH3T3 CELLS
By increasing the Dox concentration, the cytotoxicity 
reduced dramatically (p<0.05). Since the IC50 for T47D 
cells was lower than that for more resistant HT29 cells, 
they showed higher viability compared to T47D cells. 
Exposuring the cells to the Dox loaded NPs, indicated a 
range of cytotoxicity responses which were almost 
equal to the cytotoxicity caused by Dox solutions.  
Since Dox release from NPs needed three days, the 
latter observation could prove an effective uptake of 
NPs by the cells. Results of this study demonstrated 
that the MTT assay could be implemented as an 
effective and sensitive tool to assess cytotoxicity of 
PCLF NPs on cells. 
Cellular uptake of NPs: Consistent with the results of 
confocal microscopy (Figure 6), fluorescence signals 
were detected in the T47D cells after 48 hours 
incubation with FITC loaded PCLF NPs. Figure 6, A, 
shows T47D cells incubated with PCLF1250 NPs in 
RPMI medium. As there was no fluorescent agent in 
the formulation, naturally no fluorescence color was 
observed in the image. Figure 6, B, the image of 
incubation of the T47D cells with FITC loaded PCLF1250 
NPs, showed green fluorescence inside the cells, 
especially in the perinuclear region, revealing the 
cellular uptake of the NPs.  As the intense fluorescence 
color in the image represents, such NP uptake by T47D 
cell line was predominant.  
 
FIGURE 6: IMAGES FROM FLUORESCENT MICROSCOPE TO 
INVESTIGATE THE POSSIBILITY OF PCLF NPs CELLULAR UPTAKE; 
A: T47D cells exposured by PCLF NPs, B: T47D cells exposured by 
FITC loaded PCLF NPs, C: T47D cells exposured by RPMI alone, D: 
T47D cells exposured by RPMI and acetone 
Figure 6, C and D, were controls showing the cells 
incubated with RPMI alone and RPMI with acetone, 
respectively. These images demonstrate that the RPMI 
medium and the acetone (which can be a residue of 
the NP preparation process) could not make any 
fluorescence signal in the image. Therefore, the 
intracellular fluorescence of T47D cells (Figure 6, A), 
proved the ability of these cells to uptake the PCLF 
NPs.  
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In vivo distribution of NPs: Experiments showed that 
DiR excitation and emission was at 670 and  790 nm, 
respectively. This allows us to obtain a significant signal 
with very low background level and therefore a high 
resolution (8). Table 1 shows the values of DiR loading 
into the PCLF NPs and figure 7 shows DiR release 
profiles. DiR was released from PCLF530 NPs in 4 days 
(70%) and from PCLF 1250, 2000 and PCL NPs in 6 days 
(60, 60 and 80%, respectively). 
 
FIGURE 7: DiR RELEASE FROM PCLF NPs 
Therefore, fortunately most of the DiR was remained 
in the NPs and not released during the 3 days of in vivo 
imaging experiment. 
The distribution of DiR solution and DiR loaded NPs 
were explored over three days following intracardial 
injections to mice (which have similar size of lymphatic 
capillaries as those in humans-10-80 µm). According to 
the in vivo images (Figures 8-11) it was found that both 
DiR and NPs entered the liver after 30 minutes but the 
NPs continued to enter and remain in other organs 
such as spleen and axillary and terminal lymph nodes, 
while DiR excreted slowly from the body after few 
hours. 
 
FIGURE 8: NOT INJECTED MICE 
 
FIGURE 9: IMAGES AT TIME: 0 (AFTER INJECTION) 
 
FIGURE 10: DISTRIBUTION OF PCLF2000 NPs 
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FIGURE 11: COMPARISON OF PCLF2000 NPs AND DiR
It can be concluded that the NPs were taken up into 
the lymphatic nodes and that they were retained in the 
lymph nodes for two days. The ability of such ligand-
less NPs to deliver drugs to macrophages in lymph 
nodes, offers a promising approach to immunotherapy 
and lymphoma therapy 7.  
Lymph node retention time of NPs has been 
investigated by several other researchers and typically 
has focused on time points in the range of 6-52 hours 
post-injection 8.  
 
FIGURE 12: MOUSE INJECTED BY DiR LOADED PCLF2000 NPs 
SUSPENSION (A) AND DiR SOLUTION (B), INTO HEART, AFTER 72 
HOURS 
This study examined lymph node retention of NPs up 
to 72 hours, and showed that 200-300 nm PCLF NPs 
were significantly present at qualitatively consistent 
levels in lymph nodes at 24, 48 and 72 hours following 
a bolus intracardial injection of 20 µl of samples. 
Images of mice injected by formulations were 
quantitatively analyzed (Figures 13-16). For every 
organ of the mouse body, the mean intensity of light 
was measured which represented the concentration of 
the formulation in that organ.  
 
FIGURE 13: MEAN INTENSITY OF DiR FLUORESCENT IN HEART OF 
MOUSE INJECTED by DiR LOADED PCLF2000 NPs SUSPENSION 
AND DiR SOLUTION 
 
FIGURE 14: MEAN INTENSITY OF DiR FLUORESCENT IN LIVER AND 
SPLEEN OF MOUSE INJECTED BY DiR LOADED PCLF2000 NPs 
SUSPENSION AND DIR SOLUTION 
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FIGURE 15: MEAN INTENSITY OF DiR FLUORESCENT IN NECK, 
HAND, LEG AND GENITAL SYSTEM OF MOUSE INJECTED BY DiR 
LOADED PCLF2000 NPs SUSPENSION AND DiR SOLUTION 
 
FIGURE 16: MEAN INTENSITY OF DiR FLUORESCENT IN BLADDER 
OF MOUSE INJECTED BY DiR LOADED PCLF2000 NPs SUSPENSION 
AND DIR SOLUTION 
For instance, figure 11 presents a comparison of the 
images of mice injected by the PCLF2000 NP 
suspension and DiR solution, after 3 days, which not 
only reveals the absence of DiR and the existence of 
the NPs in the body, but also shows the organs with 
high concentrations of the NPs, i.e. liver, spleen, hands, 
legs and genital system. Therefore, NP accumulation 
was occurred in these organs in contrast to the 
abdominal region which seemed empty and the 
bladder which did not show a dense color.  
As it can be observed in the figures, DiR solution was 
eliminated from mouse body after about one hour 
post injection because the most density in the image 
was belonged to the bladder and not to the liver 
(Figure 12 and 15).  
Suspensions of PCLF530 NPs, PCLF1250 NPs and 
PCLF2000 NPs were distributed in the body while just 
part of them was eliminated from the body (via urine) 
even after one to three days post injection (Figure 12 
and 15). 
CONCLUSION: PCLF copolymers with three different 
Mw (named PCLF530, PCLF1250 and PCLF2000) were 
used to prepare NPs. Dox loaded NPs showed 
controlled release duration of 4 days in PBS pH 5.8 
with a higher maximum release compared to that in pH 
7.4. 
The cytotoxicity test of PCLF NPs on T47D, HT29 and 
3T3NIH cells revealed that not only the empty PCLF 
NPs did not cause a considerable cytotoxicity and there 
was no significant difference between cytotoxicities of 
NPs of PCLF530, 1250 and 2000, but also the Dox 
loaded PCLF NPs showed great cytotoxicities which 
were in most cases equal to their corresponded 
concentration of Dox solutions.  
Such results could additionally indicate that the NPs 
could be uptaken by these cells because the release 
duration of Dox from NPs was 4 days. Moreover, in 
cellular uptake test, the intracellular fluorescence of 
T47D cells, 48 hours after incubation with FITC loaded 
PCLF1250 NPs, proved the ability of these cells to 
uptake the PCLF NPs. 
DiR fluorescent agent could load efficiently into the 
NPs and fortunately it did not show a fast release from 
NPs. Therefore, DiR could make NPs visible using in 
vivo imaging system. Comparison of images of the mice 
injected by DiR solution and DiR loaded NPs, revealed 
that in contrast to the DiR solution, DiR loaded NPs 
could remain in the mice body for a few days. 
Moreover, the NPs entered into the lymph node rich 
organs and were entrapped there after 1 day after 
injection. The injected mice did not show toxic 
symptoms or death following injection, confirming the 
cell cytotoxicity results.   
ACKNOWLEDGEMENTS: The authors would like to 
express their sincere gratitude to Mehdi Gholami, 
Department of Pharmacology and Toxicology, and 
Hamed Hashemi, Faculty of pharmacy, Tehran 
University of Medical Sciences, for his assistance with 
the in vivo experiments. 
          Shokri et al., IJPSR, 2012; Vol. 3(9): 3106-3115                                    ISSN: 0975-8232 
                                           Available online on www.ijpsr.com                                        3115 
REFERENCES: 
1. Yang R., Cui F., Cheng G., Han X., Jin Q., Kim D., Chung S., Shim 
C., 2009. Enhanced electrostatic interaction between chitosan-
modified PLGA nanoparticle and tumor. Int. J. Pharm. 371(1-2) 
1986, 142-7. 
2. Matsumura Y. A new concept for macromolecular therapeutics 
in cancer chemotherapy: mechanism of tumor tropic 
accumulation of proteins and antitumor agent SMANCS. Cancer 
Res. 46, 6387-92. 
3. Kim Y., Lee Y. Poly(ethylene oxide)-poly(propylene oxide)-
poly(ethylene oxide)/poly(caprolactone) (PCL) amphiphilic 
block copolymeric nanospheres: II. Thermo-responsive drug 
release behaviors. J. Cont. Rel. 65 2000. 345-58. 
4. Vinardell M. In Vitro Cytotoxicity of Nanoparticles in 
Mammalian Germ-Line Stem Cell. Oxford Journals. Life Sciences 
& Medicine. Toxicological Sciences. 88 (2), 285-286. 
5. Long J. The Gale Encyclopedia of Cancer; A Guide to Cancer and 
Its Treatments; Oncology Encyclopedia. Jun 4, 2010. 
6. Rao J., Dragulescu-Andrasi A., Yao H., 2007. Fluorescence 
imaging in vivo: recent advances. Current Opinion in 
Biotechnology. 18, 17-25. 
7. Ravizzini G., Turkbey B., Barrett T., Kobayashi H., Choyke P., 
2009. Nanoparticles in sentinel lymph node mapping, Wiley, 
Interdisciplinary reviews, Wires nanomedicine and 
nanobiotechnology. 1(6), 610-623. 
8. Reddy S., Rehor A., Schmoekel H., Hubbell J., Swarts M., 2006. 
In vivo targeting of dendritic cells in lymph nodes with poly 
(propylene sulfide) nanoparticles. J. cont. rel. 112(1), 26-34.  
9. Heng M., Wei Sh., Zhiqing P., Huafang W., Weiyue L., Xinguo J., 
Jun D., Tao G., Yu H., EGFP-EGF1 protein-conjugated PEGePLA 
nanoparticles for tissue factor targeted drug delivery, 2010. 
Biomaterials. 31, 5619-5626. 
10. Hyunah C., Guilherme L., Jamey W., Ho-Chul Sh., Glen S., 2011. 
In Vivo Cancer Imaging by Poly(ethylene glycol)-b-poly(ɛ-
caprolactone) Micelles Containing a Near-infrared Probe. Nano. 
06-009. 
11. Yu X., Liang L., Xueqing W., Jiancheng W., Xuan Z., Qiang Z., 
2011. Chloride channel-mediated brain glioma targeting of 
chlorotoxin-modified doxorubicin-loaded liposomes. J. cont. rel. 
03-014. 
12. Kalchenko V., Harmelin A., Shivtiel Sh., Malina V., Lapid K., 
Haramati Sh., Lapidot T.,2006. Use of lipophilic near-infrared 
dye in whole-body optical imaging of hematopoietic cell 
homing. J. Biomed. Opt. 11(5), 050507. 
13. Park D., Sun B., Chung H., Im S., Choi Y., Park K., Huh K., 2007. In 
vitro and in vivo test of PEG/PCL-based hydrogel scaffold for cell 
delivery application. J. Cont. Rel. 124(1-2), 51-9. 
14. Zhou Sh., Yang H., 2003. Biodegradable poly(caprolactone)-
poly(ethylene glycol) block copolymers: characterization and 
their use as drug carriers for a controlled delivery system 
Biomaterials. 24(20), 3563-70. 
15. Huatan H., Attwood D., 1995. The microencapsulation of 
protein using a novel ternary blend based on poly 
(caprolactone). J Microencapsulation. 12, 557-67. 
 
 
 
16. Peng H., Liu J., Zhu N., Ni X., Shen Z., 2010. Controlled 
enzymatic degradation of poly(caprolactone)-based copolymers 
in the presence of porcine pancreatic lipase. Polymer 
Degradation and Stability. 95(4), 643-50. 
17. Wei X., Gou M., Fu Sh., Guo Q., Shi Sh., Luo F., Guo G., Qiu L., 
Qian Z., 2009. Biodegradable poly(caprolactone)-poly(ethylene 
glycol) copolymers as drug delivery system. Int. J. Pharm. 
381(1), 1-18. 
18. Gou M., Peng X., Men K., Zheng X., Zeng Sh., Guo G., Luo F., 
Zhao X., Chen L., Wei Y., Qian Z., 2009. Poly(caprolactone)-
poly(ethylene glycol)-poly(caprolactone) (PCL-PEG PCL) 
nanoparticles for honokiol delivery in vitro. Int. J. Pharm. 375(1-
2), 170-6. 
19. Shokri N., Akbari Javar H., Fouladdel Sh., Khalaj A., Khoshayand 
MR., Atyabi F., Nomani A., Azizi E., Dinarvand R., 2011. 
Preparation and evaluation of poly(caprolactone fumarate) 
nanoparticles containing doxorubicin HCl. Daru J. Pharm. ScI. 
19, 1.      
20. Shokri N., Akbari Javar H., Fouladdel Sh., Khalaj A., Dinarvand 
R., Azizi E.,2011. Preparation and characterization of 
crosslinked and non-crosslinked polycaprolactone fumarate 
(PCLF) NPs as carriers for doxorubicin HCl, African J. Pharmacy 
and Pharmacology. 5(7), 797-805. 
21. Wang Sh., Lu L., Gruetzmacher J., Currier B., Yaszemski M., 
2006. Synthesis and characterizations of biodegradable and 
crosslinkable poly(e-caprolactone fumarate), poly(ethylene 
glycol fumarate), and their amphiphilic copolymer. 
Biomaterials. 27, 832-41. 
22. Wang Sh., Yaszemski M., Knight A., Gruetzmacher J, Windebank 
A., Lu L., 2009. Photo crosslinked poly(e-caprolactone 
fumarate) networks for guided peripheral nerve regeneration: 
Material properties and preliminary biological evaluations. Acta 
Biomaterialia. 5, 1531-42. 
23. Wang Sh, Kempen D., Yaszemski M., Lu L., 2009. The roles of 
matrix polymer crystallinity and hydroxyapatite nanoparticles in 
modulating material properties of photo crosslinked 
composites and bone marrow stromal cell responses. 
Biomaterials. 30, 3359-3370. 
24. Wang Sh., Yaszemski M., Gruetzmacher J., Lu L., 2008. 
Photocrosslinked poly(caprolactone fumarate) networks: Roles 
of crystallinity and crosslinking density in determining 
mechanical properties. Polymer. 49, 5692-9. 
25. Heungsoo Sh., Mikos A., Jansen J., 2003. In vivo bone and soft 
tissue response to injectable, biodegradable 
oligo(poly(ethylene glycol) fumarate) hydrogels. Biomaterials. 
24, 3201-11. 
26. Dirk W., Grijpma Q., Feijen J., 2005. Preparation of 
biodegradable networks by photo crosslinking lactide, ε-
caprolactone and trimethylene carbonate-based oligomers 
functionalized with fumaric acid monoethyl ester. Biomaterials. 
26, 2795-802. 
27. Paliwal R., Rai Sh., Vaidya B., Khatri K., Goyal A., Mishra N., 
Mehta A., Vyas S., 2009. Effect of lipid core material on 
characteristics of solid lipid nanoparticles designed for oral 
lymphatic delivery. Nanomedicine. 5, 184-191. 
 
 
How to cite this article: 
Shokri N, Azizi E, Javar HA, Sh. Fouladdel, Khalaj A and Dinarvand R: 
In vitro and in vivo Evaluation of Poly(Caprolactone Fumarate) 
Nanoparticles. Int J Pharm Res Sci. 3(9); 3106-3115. 
 
